The inhibitory effect of doxycycline on cisplatin-sensitive and -resistant epithelial ovarian cancer.
<h4>Background</h4>Detecting a new effective and hypotoxic anticancer drug is an emerging new strategy for cancer chemotherapy. Doxycycline (DC) is a kind of antibiotics but also inhibits tumorigenesis.<h4>Methods</h4>MTT and cell invasion assay, flow cytometry, western-blot...
Guardado en:
Autores principales: | Wei Wu, Li-Hua Yu, Bei Ma, Ming-Juan Xu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fee10e1eb0e14229a6adecb88761f271 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer
por: PengMing Sun, et al.
Publicado: (2018) -
Ghrelin enhances cisplatin sensitivity in HO-8910 PM human ovarian cancer cells
por: Yun Leng, et al.
Publicado: (2021) -
Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer
por: Bortot B, et al.
Publicado: (2020) -
DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer
por: Riikka J. Lund, et al.
Publicado: (2017) -
Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
por: Christine S Walsh, et al.
Publicado: (2021)